QurientQurient

팝업레이어 알림

팝업레이어 알림이 없습니다.

최신글

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

  • Notice

      2023-09-18 신주배정기준일 및 주식명의개서 정지공고
      2023-09-18 주주 공지문
      2023-09-18 신주발행공고
      2023-08-18 한국IR협의회 큐리언트 분석 리포트
      2023-04-27 SK증권 큐리언트 분석 리포트
  • Press Release

      2023-09-14 큐리언트, Q901 1상 최저용량서 말기 췌장암 부분관해 확인
      2023-08-29 큐리언트, 세계적 항암 연구 병원과 공동 연구 확대
      2023-08-24 큐리언트, 국제학회서 항암신약 2종 임상현황 잇달아 발표
      2023-08-14 큐리언트, 美국립암연구소와 항암제 공동연구개발 계약
      2023-08-01 큐리언트, 제약산업 전주기 글로벌 진출 지원 사업 선정
  • Company

    Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More

  • Business philosophy

    Innovation for unmet medical needs

    Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More

  • Pipeline

    Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More

  • IR/PR

    Dear Qurient shareholders

    Qurient would like to share brief updates on current progress made on its portfolio programs. See More

information for download file